UK biotech inks stem cell engineering deal with Singapore researchers

By Staff Reporter

- Last updated on GMT

Image: iStock/selvanegra
Image: iStock/selvanegra

Related tags: Stem cell, Bone marrow

Plasticell has partnered with Singapore’s Agency for Science, Technology and Research (A*STAR) and the Nanyang Technological University (NTU) to advance its stem cell pipeline.

Stevenage, UK-based Plasticell is investigating the use of hematopoietic stem cell in the treatment of over 70 different therapeutic indications and has struck technology licensing, collaborative research and scientific exchange visit agreements with the two Singapore research centres.

Proprietary genome editing technology at NTU and A*STAR will be applied to insert functional multi-transgene cassettes into specific loci of human stem cell lines.

“Technology is based on the use of an engineered recombinase to insert transgenes into a safe harbour site that is functional in hESC and their differentiated progeny,”​ Plasticell’s founder and executive chairman Dr Yen Choo told Biopharma-Reporter.com.

“The technology is an alternative to conventional genome editing technology which is difficult to apply to engineering of pluripotent stem cells.”

These engineered lines will then be used by Plasticell in a number of projects looking at directed stem cell differentiation, phenotypic screening for drug discovery and in next-generation immuno-oncology applications.

Singapore swing

The selection of government-funded research organisation A*STAR and the local University was due to both having “considerable, long-standing expertise and technology in the stem cell area,” Choo said.

“Therefore Plasticell is looking at these relationships strategically, as well as the growing importance of Asia in the stem cell field. Singapore has a substantial, incremental science budget and a policy of encouraging engagement with industrial partners.”

Plasticell itself has developed potent media compositions to expand hematopoetic stem cells in vitro by factors of up to 500-fold and, according to the firm,  is developing GMP-compliant bioprocesses for manufacture of cord blood CB and bone marrow therapies.

Related topics: Bio Developments, Pipelines, Cell lines

Related news

Show more

Related products

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Related suppliers

Follow us

Products

View more

Webinars